

# Abraham S Kanate

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4155184/publications.pdf>

Version: 2024-02-01

27  
papers

831  
citations

567281

15  
h-index

526287

27  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1694  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	1.4	246
2	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	4.1	61
3	Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4424-4428.	3.2	60
4	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€cell lymphoma, nasal type: a <sc>CIBMTR</sc> analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	2.5	59
5	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamideâ€Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
6	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
7	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
8	Hematopoietic progenitor cell mobilization with â€just-in-timeâ€plerixafor approach is a cost-effective alternative to routine plerixafor use. <i>Cytotherapy</i> , 2015, 17, 1785-1792.	0.7	30
9	Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. <i>World Journal of Stem Cells</i> , 2014, 6, 69.	2.8	29
10	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
11	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
12	Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 307-314.	1.9	25
13	Treatment of severe mucositis pain with oral ketamine mouthwash. <i>Supportive Care in Cancer</i> , 2017, 25, 2215-2219.	2.2	23
14	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
15	Predictors and Impact of Thirty-Day Readmission on Patient Outcomes and Health Care Costs after Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 415-420.	2.0	16
16	Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation. <i>Leukemia Research and Treatment</i> , 2017, 2017, 1-6.	2.0	16
17	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
18	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11

#	ARTICLE	IF	CITATIONS
19	Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1295-1302.	2.0	8
20	Single versus double-unit transfusion: Safety and efficacy for patients with hematologic malignancies. <i>European Journal of Haematology</i> , 2019, 102, 383-388.	2.2	8
21	Salvage Bone Marrow Harvest in Patients Failing Plerixafor-Based Stem Cell Mobilization Attempt: Feasibility and Autologous Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1133-1135.	2.0	5
22	Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. <i>Supportive Care in Cancer</i> , 2016, 24, 4237-4240.	2.2	5
23	Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Advances in Hematology</i> , 2017, 2017, 1-4.	1.0	5
24	Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma. <i>Bone Marrow Research</i> , 2012, 2012, 1-11.	1.7	2
25	Prospective assessment of <i>Clostridioides</i> (formerly <i>Clostridium</i> ) <i>difficile</i> colonization and acquisition in hematopoietic stem cell transplant patients. <i>Transplant Infectious Disease</i> , 2020, 22, e13438.	1.7	1
26	Impact of anti-aerobic antibiotic activity on graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling. <i>Transplant Infectious Disease</i> , 2021, 23, e13676.	1.7	1
27	Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 349-352.	1.0	0